ReviewCancers2020

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.

Masatoshi KudoPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.